Oncotelic Therapeutics, Inc. (0000908259) (Filer)

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

Current Report

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported)

October 26, 2026

ONCOTELIC THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

29397 Agoura Road, Suite 107

Agoura Hills, CA 91301

(Address of principal executive offices and Zip Code)

Registrant’s telephone number, including area code

(650) 635-7000

Not applicable.

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

Securities registered pursuant to Section 12(b) of the Act:

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01 Other Events.

On October 22, 2026, Saran Saund, Chief Business Officer of Oncotelic Therapeutics Inc. made a presentation at the 22nd Drug Discovery Strategic Summit, October 21–22, 2026 at the Westin San Francisco Airport, Millbrae, California. The presentation titled “Partitioning 29 Million PubMed Abstracts by Disease Turns a Literature Review into a Discovery. A Four-Gene mTOR Signature Defining a Candidate Hepatocellular Carcinoma Population.”, is included as an exhibit to this Current Report on Form 8-K.

The presentation described the Company’s Partitioned Literature Aggregation (“PLA”) framework and its application in liver cancer research, where literature analysis was combined with gene-expression and survival analyses to identify a four-gene mTOR-related signature associated with patient outcomes. It also outlined the Company’s proposed expansion of PLA through autonomous AI agents and a planned research environment targeting 100 billion protein-related vectors to support drug discovery across multiple disease areas.

A hyperlink to the event is provided herewith: DDSS conference details

Disclaimer.

The information in Section 8.01 of this Current Report on Form 8-K, including the information set forth in exhibit 99.1, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), nor be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.